Annual CFI
$46.45 M
+$92.61 M+200.63%
31 December 2023
Summary:
Lineage Cell Therapeutics annual cash flow from investing activities is currently $46.45 million, with the most recent change of +$92.61 million (+200.63%) on 31 December 2023. During the last 3 years, it has risen by +$33.41 million (+256.26%). LCTX annual CFI is now at all-time high.LCTX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$3.89 M
+$12.68 M+144.22%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly cash flow from investing activities is currently $3.89 million, with the most recent change of +$12.68 million (+144.22%) on 30 September 2024. Over the past year, it has increased by +$1.77 million (+83.22%). LCTX quarterly CFI is now -79.71% below its all-time high of $19.16 million, reached on 30 June 2023.LCTX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$4.80 M
+$1.77 M+58.23%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM cash flow from investing activities is currently $4.80 million, with the most recent change of +$1.77 million (+58.23%) on 30 September 2024. Over the past year, it has dropped by -$26.81 million (-84.82%). LCTX TTM CFI is now -89.67% below its all-time high of $46.45 million, reached on 31 December 2023.LCTX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +200.6% | +83.2% | -84.8% |
| 3 y3 years | +256.3% | +5817.6% | -55.5% |
| 5 y5 years | +293.1% | -71.2% | -81.6% |
LCTX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +200.6% | -79.7% | +109.5% | -89.7% | +110.4% |
| 5 y | 5 years | at high | +200.6% | -79.7% | +109.5% | -89.7% | +110.4% |
| alltime | all time | at high | +200.6% | -79.7% | +109.5% | -89.7% | +110.4% |
Lineage Cell Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.89 M(-144.2%) | $4.80 M(+58.2%) |
| June 2024 | - | -$8.79 M(>+9900.0%) | $3.03 M(-90.2%) |
| Mar 2024 | - | -$38.00 K(-100.4%) | $30.98 M(-33.3%) |
| Dec 2023 | $46.45 M(-200.6%) | $9.74 M(+359.1%) | $46.45 M(+47.0%) |
| Sept 2023 | - | $2.12 M(-88.9%) | $31.61 M(-376.5%) |
| June 2023 | - | $19.16 M(+24.2%) | -$11.43 M(-62.7%) |
| Mar 2023 | - | $15.43 M(-402.4%) | -$30.69 M(-33.5%) |
| Dec 2022 | -$46.16 M(-573.7%) | -$5.10 M(-87.5%) | -$46.16 M(+12.0%) |
| Sept 2022 | - | -$40.91 M(>+9900.0%) | -$41.20 M(>+9900.0%) |
| June 2022 | - | -$97.00 K(+110.9%) | -$357.00 K(-4.8%) |
| Mar 2022 | - | -$46.00 K(-68.5%) | -$375.00 K(-103.8%) |
| Dec 2021 | $9.74 M(-25.3%) | -$146.00 K(+114.7%) | $9.74 M(-9.7%) |
| Sept 2021 | - | -$68.00 K(-40.9%) | $10.79 M(-2.2%) |
| June 2021 | - | -$115.00 K(-101.1%) | $11.04 M(-38.2%) |
| Mar 2021 | - | $10.07 M(+1016.9%) | $17.86 M(+37.0%) |
| Dec 2020 | $13.04 M(-23.1%) | $902.00 K(+406.7%) | $13.04 M(+1.4%) |
| Sept 2020 | - | $178.00 K(-97.3%) | $12.86 M(-50.9%) |
| June 2020 | - | $6.70 M(+27.5%) | $26.16 M(+35.8%) |
| Mar 2020 | - | $5.26 M(+630.0%) | $19.27 M(+13.6%) |
| Dec 2019 | $16.96 M(+43.5%) | $720.00 K(-94.7%) | $16.96 M(-34.8%) |
| Sept 2019 | - | $13.48 M(-7051.0%) | $26.02 M(+109.9%) |
| June 2019 | - | -$194.00 K(-106.6%) | $12.40 M(-1.2%) |
| Mar 2019 | - | $2.95 M(-69.9%) | $12.55 M(+6.2%) |
| Dec 2018 | $11.82 M(-215.6%) | $9.78 M(-7189.9%) | $11.82 M(+715.5%) |
| Sept 2018 | - | -$138.00 K(+236.6%) | $1.45 M(+9.0%) |
| June 2018 | - | -$41.00 K(-101.9%) | $1.33 M(+16.6%) |
| Mar 2018 | - | $2.21 M(-479.2%) | $1.14 M(-111.1%) |
| Dec 2017 | -$10.22 M(-6.1%) | -$583.00 K(+126.0%) | -$10.22 M(+1.7%) |
| Sept 2017 | - | -$258.00 K(+12.2%) | -$10.05 M(-2.0%) |
| June 2017 | - | -$230.00 K(-97.5%) | -$10.26 M(-44.2%) |
| Mar 2017 | - | -$9.15 M(+2138.1%) | -$18.38 M(+68.8%) |
| Dec 2016 | -$10.89 M(+46.3%) | -$409.00 K(-11.9%) | -$10.89 M(-16.7%) |
| Sept 2016 | - | -$464.00 K(-94.4%) | -$13.07 M(-10.7%) |
| June 2016 | - | -$8.35 M(+401.6%) | -$14.63 M(+67.5%) |
| Mar 2016 | - | -$1.67 M(-35.7%) | -$8.73 M(+17.4%) |
| Dec 2015 | -$7.44 M(+638.2%) | -$2.59 M(+27.7%) | -$7.44 M(+47.0%) |
| Sept 2015 | - | -$2.03 M(-17.4%) | -$5.06 M(+61.9%) |
| June 2015 | - | -$2.45 M(+557.6%) | -$3.13 M(+266.4%) |
| Mar 2015 | - | -$373.00 K(+78.5%) | -$853.40 K(-15.3%) |
| Dec 2014 | -$1.01 M(-72.5%) | -$209.00 K(+127.2%) | -$1.01 M(-59.0%) |
| Sept 2014 | - | -$92.00 K(-48.7%) | -$2.46 M(-31.4%) |
| June 2014 | - | -$179.40 K(-66.0%) | -$3.58 M(-1.6%) |
| Mar 2014 | - | -$527.60 K(-68.2%) | -$3.64 M(-0.6%) |
| Dec 2013 | -$3.67 M(+3400.5%) | -$1.66 M(+36.2%) | -$3.67 M(+66.4%) |
| Sept 2013 | - | -$1.22 M(+409.4%) | -$2.20 M(+112.4%) |
| June 2013 | - | -$239.00 K(-56.6%) | -$1.04 M(+92.7%) |
| Mar 2013 | - | -$550.60 K(+181.1%) | -$538.10 K(+414.4%) |
| Dec 2012 | -$104.70 K(-91.3%) | -$195.90 K(+279.7%) | -$104.60 K(+17.9%) |
| Sept 2012 | - | -$51.60 K(-119.8%) | -$88.70 K(-68.3%) |
| June 2012 | - | $260.00 K(-322.0%) | -$279.70 K(-64.2%) |
| Mar 2012 | - | -$117.10 K(-34.9%) | -$781.90 K(-35.0%) |
| Dec 2011 | -$1.20 M(-137.6%) | -$180.00 K(-25.8%) | -$1.20 M(-141.7%) |
| Sept 2011 | - | -$242.60 K(+0.2%) | $2.88 M(+1.0%) |
| June 2011 | - | -$242.20 K(-55.0%) | $2.85 M(-1.8%) |
| Mar 2011 | - | -$538.00 K(-113.8%) | $2.91 M(-9.1%) |
| Dec 2010 | $3.20 M(-7020.8%) | $3.90 M(-1537.2%) | $3.20 M(-548.4%) |
| Sept 2010 | - | -$271.70 K(+42.9%) | -$713.10 K(+52.7%) |
| June 2010 | - | -$190.10 K(-22.6%) | -$467.00 K(+64.1%) |
| Mar 2010 | - | -$245.70 K(+4287.5%) | -$284.60 K(+516.0%) |
| Dec 2009 | -$46.20 K(-94.9%) | -$5600.00(-78.1%) | -$46.20 K(-69.0%) |
| Sept 2009 | - | -$25.60 K(+232.5%) | -$149.10 K(-77.9%) |
| June 2009 | - | -$7700.00(+5.5%) | -$673.50 K(-26.5%) |
| Mar 2009 | - | -$7300.00(-93.3%) | -$915.80 K(+0.6%) |
| Dec 2008 | -$909.90 K | -$108.50 K(-80.3%) | -$909.90 K(+12.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2008 | - | -$550.00 K(+120.0%) | -$806.10 K(+214.8%) |
| June 2008 | - | -$250.00 K(>+9900.0%) | -$256.10 K(+4098.4%) |
| Mar 2008 | - | -$1400.00(-70.2%) | -$6100.00(-6.2%) |
| Dec 2007 | -$6500.00(-39.3%) | -$4700.00(<-9900.0%) | -$6500.00(0.0%) |
| Sept 2007 | - | $0.00(0.0%) | -$6500.00(-47.6%) |
| June 2007 | - | $0.00(-100.0%) | -$12.40 K(0.0%) |
| Mar 2007 | - | -$1800.00(-61.7%) | -$12.40 K(+17.0%) |
| Dec 2006 | -$10.70 K(<-9900.0%) | -$4700.00(-20.3%) | -$10.60 K(+79.7%) |
| Sept 2006 | - | -$5900.00(<-9900.0%) | -$5900.00(<-9900.0%) |
| June 2006 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2006 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2005 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2004 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2003 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2003 | - | $0.00(0.0%) | -$3800.00(0.0%) |
| June 2003 | - | $0.00(0.0%) | -$3800.00(0.0%) |
| Mar 2003 | - | $0.00(-100.0%) | -$3800.00(0.0%) |
| Dec 2002 | -$3800.00(-25.5%) | -$3800.00(<-9900.0%) | -$3800.00(<-9900.0%) |
| Sept 2002 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2002 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2002 | - | $0.00(0.0%) | -$3600.00(-29.4%) |
| Dec 2001 | -$5100.00(-84.7%) | $0.00(0.0%) | -$5100.00(0.0%) |
| Sept 2001 | - | $0.00(-100.0%) | -$5100.00(-47.4%) |
| June 2001 | - | -$3600.00(+140.0%) | -$9700.00(-64.6%) |
| Mar 2001 | - | -$1500.00(<-9900.0%) | -$27.40 K(-18.0%) |
| Dec 2000 | -$33.40 K(-79.3%) | $0.00(-100.0%) | -$33.40 K(-64.9%) |
| Sept 2000 | - | -$4600.00(-78.4%) | -$95.10 K(+5.1%) |
| June 2000 | - | -$21.30 K(+184.0%) | -$90.50 K(-46.5%) |
| Mar 2000 | - | -$7500.00(-87.8%) | -$169.20 K(+4.6%) |
| Dec 1999 | -$161.70 K(<-9900.0%) | -$61.70 K(<-9900.0%) | -$161.70 K(+61.7%) |
| Sept 1999 | - | $0.00(-100.0%) | -$100.00 K(0.0%) |
| June 1999 | - | -$100.00 K(<-9900.0%) | -$100.00 K(<-9900.0%) |
| Mar 1999 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 1998 | $0.00(-100.0%) | - | - |
| Sept 1998 | - | $0.00(0.0%) | -$100.00 K(0.0%) |
| June 1998 | - | $0.00(0.0%) | -$100.00 K(0.0%) |
| June 1998 | -$100.00 K(<-9900.0%) | - | - |
| Mar 1998 | - | $0.00(-100.0%) | -$100.00 K(0.0%) |
| Dec 1997 | - | -$100.00 K(<-9900.0%) | -$100.00 K(<-9900.0%) |
| Sept 1997 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 1997 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1997 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 1996 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 1996 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 1996 | $0.00(-100.0%) | - | - |
| Sept 1995 | - | $0.00(-100.0%) | $4.90 M(0.0%) |
| June 1995 | $4.90 M(-258.1%) | $3.00 M(>+9900.0%) | $4.90 M(+157.9%) |
| Mar 1995 | - | $0.00(-100.0%) | $1.90 M(-161.3%) |
| Dec 1994 | - | $1.90 M(>+9900.0%) | -$3.10 M(0.0%) |
| Sept 1994 | - | $0.00(0.0%) | -$3.10 M(0.0%) |
| June 1994 | -$3.10 M(+55.0%) | $0.00(-100.0%) | -$3.10 M(-39.2%) |
| Mar 1994 | - | -$5.00 M(-363.2%) | -$5.10 M(+5000.0%) |
| Dec 1993 | - | $1.90 M(>+9900.0%) | -$100.00 K(-95.0%) |
| Sept 1993 | - | $0.00(-100.0%) | -$2.00 M(0.0%) |
| June 1993 | -$2.00 M(<-9900.0%) | -$2.00 M(<-9900.0%) | -$2.00 M(<-9900.0%) |
| Mar 1993 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 1992 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 1992 | - | $0.00 | $0.00 |
| June 1992 | $0.00 | - | - |
FAQ
- What is Lineage Cell Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual CFI year-on-year change?
- What is Lineage Cell Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly CFI year-on-year change?
- What is Lineage Cell Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM CFI year-on-year change?
What is Lineage Cell Therapeutics annual cash flow from investing activities?
The current annual CFI of LCTX is $46.45 M
What is the all time high annual CFI for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual cash flow from investing activities is $46.45 M
What is Lineage Cell Therapeutics annual CFI year-on-year change?
Over the past year, LCTX annual cash flow from investing activities has changed by +$92.61 M (+200.63%)
What is Lineage Cell Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of LCTX is $3.89 M
What is the all time high quarterly CFI for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly cash flow from investing activities is $19.16 M
What is Lineage Cell Therapeutics quarterly CFI year-on-year change?
Over the past year, LCTX quarterly cash flow from investing activities has changed by +$1.77 M (+83.22%)
What is Lineage Cell Therapeutics TTM cash flow from investing activities?
The current TTM CFI of LCTX is $4.80 M
What is the all time high TTM CFI for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM cash flow from investing activities is $46.45 M
What is Lineage Cell Therapeutics TTM CFI year-on-year change?
Over the past year, LCTX TTM cash flow from investing activities has changed by -$26.81 M (-84.82%)